Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning

Objective Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. We aimed to derive HFpEF phenotype-based groups ('phenogroups') based on clinical and echocardiogram data using machine learning, and to compare clinical characteristics, proteomics and outcomes across the phenogroups. Methods We applied model-based clustering to 32 echocardiogram and 11 clinical and laboratory variables collected in stable condition from 320 HFpEF outpatients in the Karolinska-Rennes cohort study (56% female, median 78 years (IQR: 71–83)). Baseline proteomics and the composite end point of all-cause mortality or heart failure (HF) hospitalisation were used in secondary analyses. Results We identified six phenogroups, for which significant differences in the prevalence of concomitant atrial fibrillation (AF), anaemia and kidney disease were observed (p<0.05). Fifteen out of 86 plasma proteins differed between phenogroups (false discovery rate, FDR<0.05), including biomarkers of HF, AF and kidney function. The composite end point was significantly different between phenogroups (log-rank p<0.001), at short-term (100 days), mid-term (18 months) and longer-term follow-up (1000 days). Phenogroup 2 was older, with poorer diastolic and right ventricular function and higher burden of risk factors as AF (85%), hypertension (83%) and chronic obstructive pulmonary disease (30%). In this group a third experienced the primary outcome to 100 days, and two-thirds to 18 months (HR (95% CI) versus phenogroups 1, 3, 4, 5, 6: 1.5 (0.8–2.9); 5.7 (2.6–12.8); 2.9 (1.5–5.6); 2.7 (1.6–4.6); 2.1 (1.2–3.9)). Conclusions Using machine learning we identified distinct HFpEF phenogroups with differential characteristics and outcomes, as well as differential levels of inflammatory and cardiovascular proteins.

[1]  Erwan Donal,et al.  How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). , 2019, European heart journal.

[2]  G. Filippatos,et al.  Comprehensive in‐hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2018, European journal of heart failure.

[3]  L. Groop,et al.  Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.

[4]  E. Ingelsson,et al.  Circulating proteins as predictors of incident heart failure in the elderly , 2018, European journal of heart failure.

[5]  Gianluigi Savarese,et al.  A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction , 2017, European journal of heart failure.

[6]  E. Ingelsson,et al.  Use of Proteomics To Investigate Kidney Function Decline over 5 Years. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[7]  Sanjiv J. Shah,et al.  Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT , 2017, Current Heart Failure Reports.

[8]  A. Low,et al.  Thymosin Beta‐4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction , 2017, Journal of the American Heart Association.

[9]  P. Wei,et al.  Serum Endothelial Cell–Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance , 2017, Angiology.

[10]  B. van Guelpen,et al.  The Metabolic Syndrome, Inflammation, and Colorectal Cancer Risk: An Evaluation of Large Panels of Plasma Protein Markers Using Repeated, Prediagnostic Samples , 2017, Mediators of inflammation.

[11]  Sanjiv J. Shah,et al.  Mode of Death in Heart Failure With Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.

[12]  J. Daubert,et al.  Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach , 2017, Circulation. Cardiovascular genetics.

[13]  E. Hagström,et al.  Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip , 2016, Heart.

[14]  J. Blomster,et al.  Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects , 2016, Cardiovascular Diabetology.

[15]  L. Lund,et al.  Microvascular endothelial dysfunction in heart failure with preserved ejection fraction , 2016, Heart.

[16]  R. McKelvie,et al.  Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response , 2015, European journal of heart failure.

[17]  L. Lund,et al.  New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study , 2015, European journal of heart failure.

[18]  Jacob P. Kelly,et al.  Patient selection in heart failure with preserved ejection fraction clinical trials. , 2015, Journal of the American College of Cardiology.

[19]  Michael A. Burke,et al.  Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[20]  Giuseppe Ambrosio,et al.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. , 2014, European heart journal.

[21]  J. Daubert,et al.  Association between cardiovascular vs. non‐cardiovascular co‐morbidities and outcomes in heart failure with preserved ejection fraction , 2014, European journal of heart failure.

[22]  Cynthia Balion,et al.  BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure , 2014, Heart Failure Reviews.

[23]  Sanjiv J. Shah,et al.  Developing therapies for heart failure with preserved ejection fraction: current state and future directions. , 2014, JACC. Heart failure.

[24]  L. Lund,et al.  Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry , 2014, European journal of heart failure.

[25]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[26]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[27]  A. Alwan Global status report on noncommunicable diseases 2010. , 2011 .

[28]  M. Al Banchaabouchi,et al.  Antioxidant Amelioration of Dilated Cardiomyopathy Caused by Conditional Deletion of NEMO/IKK&ggr; in Cardiomyocytes , 2010, Circulation research.

[29]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Daubert,et al.  Rationale and design of the Karolinska‐Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction , 2009, European journal of heart failure.

[31]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[32]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[33]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[34]  Adrian E. Raftery,et al.  Model-Based Clustering, Discriminant Analysis, and Density Estimation , 2002 .

[35]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Kendall Statistical Methods for Research Workers , 1937, Nature.

[37]  R. Fisher,et al.  Statistical Methods for Research Workers , 1930, Nature.